Navigation Links
ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
Date:11/12/2008

oretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.

Cinryze is for intravenous use only. A dose of 1000 Units Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 4,600 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: http://www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enter
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
2. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
3. ViroPharma Announces Discontinuation of HCV-796 Development
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. ViroPharma to Present at the Natixis Bleichroeder Conference
7. ViroPharma to Present at Three Upcoming Healthcare Conferences
8. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
9. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
10. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern ... Both established medical-device providers as well as new medical-device ... region, while simultaneously looking at ways to reduce the ... Using distributors is one of the effective means to ... devices distribution market in Eastern European and provides profiles ...
(Date:9/30/2014)... New York , September 30, 2014 ... - Global Industry Analysis, Market Size, Share, Growth and ... is expected to be worth USD 20.8 billion in ... billion in 2017, growing at a CAGR of 7.3% ... fundamental elements needed for various health purposes, especially to ...
(Date:9/30/2014)... 30, 2014 In a recent ... Fluid) backflow of the Eldor spinal needle 25G, 103 ... hole pencil point spinal needles of the same gauge ... Spinal anesthesia is an excellent type of regional anesthesia ... Anesthesia, etc. It is estimated that 100 ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Mich., Nov. 9 Thomson Reuters today ... leading clinical surveillance solution that enables hospitals to identify ... clinical quality and reduce total cost of treatment. , ... no additional cost. , CareFocus 2.0 contains ...
... Shire plc (LSE: SHP, Nasdaq: ... availability of INTUNIV (TM) (guanfacine) Extended Release ... of Attention-Deficit/Hyperactivity Disorder ( ADHD ) in children ... formulation of guanfacine, is the first and only nonscheduled alpha-2A ...
Cached Medicine Technology:Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 2Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 4Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 5Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 6Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 7
(Date:9/30/2014)... 2014 issue of The FASEB Journal ... a simple blood test. This test, called the "lymphocyte genome ... than ever before, but it may eliminate the need for ... likely to develop cancer in the future. , "The ... peoples, lives," said Diana Anderson, a researcher involved in the ...
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. 29, 2014 ... -- artificial valves, hip replacements, surgical mesh and the like ... after their approval by the U.S. Food and Drug Administration, ... prominent nonprofit groups and published online Sept. 29 in ... medical device testing on lax oversight by the FDA. ...
(Date:9/30/2014)... 30, 2014 Edward D. Buckingham, M.D., ... has been approved to be a director of a ... Reconstructive Surgery (AAFPRS) fellowship program. The announcement came last ... Florida. , The Educational and Research Foundation for the ... It represents the finest postgraduate program in the world ...
(Date:9/30/2014)... NC (PRWEB) September 30, 2014 ... and caring individuals, National Children’s Oral Health ... $150,000 in grants to non-profit clinical partners. ... Affiliate Network and deliver comprehensive educational, preventive ... , Recipients include:,     Just ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Herceptin is ... cancer called HER2-positive and should remain the standard of ... findings from a long-term clinical trial. HER2-positive breast ... of breast cancer, according to the Mayo Clinic. ... countries received either Herceptin (trastuzumab) or Tykerb (lapatinib) in ...
Breaking Medicine News(10 mins):Health News:New blood test determines whether you have or are likely to get cancer 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3
... Dr. Jacob Bolotin Awards Presented at 2008 Convention, ... of,the Blind presented $100,000 in cash awards to ... achieving the,full integration of the blind into society ... Bolotin Awards honored ten innovators in the blindness,field ...
... 7 The Peer Group, a leading provider,of ... an,Informed Medical Communications (IMC) company, today announced the ... innovation in moderated,peer influence events whereby two Key ... data, product attributes, and prescribing,experience in a debate-style ...
... of potent, or ,high affinity, antibodies to fight infection. The ... it hinges on a single molecule, a growth factor, without ... do not yet understand about our immune system. In simple ... T cells, which help them. Ways in which these cells ...
... BETHLEHEM, Pa., July 7 MIKE AND IKE(R) Lemonade,Blends(TM) ... candy fans who are members of the facebook(R) community ... To view the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/justborn/33812/ ... Foundation will encourage,their fans who are active on facebook(R) ...
... Corporation (Pink,Sheets: BDRR), a medical imaging and diagnostic ... Network (OTCFN), a division of National,Financial Communications Corp., ... president of OTCFN, said, "In 2007, Bederra generated,revenues ... $471,182, or,approximately $0.01 per share, and has some ...
... Engage Contract Sales Organization And Seek New Marketing ... Partner to Promote Product in UK -, ... DDSS) today announced that it has reacquired the sales and,marketing rights ... Recordati Ireland Ltd. (Recordati). To promote its,product in the UK, the ...
Cached Medicine News:Health News:National Federation of the Blind Awards $100,000 2Health News:The Peer Group Launches Xpert Xchange(SM), an Innovation in Medical Peer Influence Programs 2Health News:Finding suggests novel ways to boost vaccination or natural defenses 2Health News:Photos: MIKE AND IKE(R) Lemonade Blends(TM) and Alex's Lemonade Stand Foundation Join facebook(R) 2Health News:Photos: MIKE AND IKE(R) Lemonade Blends(TM) and Alex's Lemonade Stand Foundation Join facebook(R) 3Health News:Bederra Corporation Retains OTC Financial Network for Investor Relations 2Health News:Bederra Corporation Retains OTC Financial Network for Investor Relations 3Health News:Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product 2
Remote Controlled, Easy to Use,Vision Tester Designed for Screening Children Ages 3 and Older.,Excellent for Pediatric and School Markets....
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Adult: Letter Acuity, Astigmatic Clock, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Medicine Products: